CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 128 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2023. The put-call ratio across all filers is 1.90 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,344,017 | -22.7% | 198,993 | +12.6% | 0.03% | -18.8% |
| Q2 2023 | $5,617,452 | +9.6% | 176,705 | -15.9% | 0.03% | -8.6% |
| Q1 2023 | $5,126,412 | -31.9% | 210,185 | -11.9% | 0.04% | -44.4% |
| Q4 2022 | $7,527,179 | +76.1% | 238,655 | +57.8% | 0.06% | +40.0% |
| Q3 2022 | $4,274,000 | +118.5% | 151,242 | +104.4% | 0.04% | +150.0% |
| Q2 2022 | $1,956,000 | -50.6% | 73,978 | -34.5% | 0.02% | -21.7% |
| Q1 2022 | $3,956,000 | -9.7% | 112,999 | -16.4% | 0.02% | 0.0% |
| Q4 2021 | $4,383,000 | +81.4% | 135,197 | +65.1% | 0.02% | +35.3% |
| Q3 2021 | $2,416,000 | +125.4% | 81,894 | +95.8% | 0.02% | +142.9% |
| Q2 2021 | $1,072,000 | +26.7% | 41,835 | -32.1% | 0.01% | +16.7% |
| Q1 2021 | $846,000 | – | 61,585 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,713,470,000 | 41.39% |
| Perceptive Advisors | 6,511,727 | $184,021,000 | 5.34% |
| Finepoint Capital LP | 536,901 | $15,173,000 | 4.99% |
| Artal Group S.A. | 2,000,000 | $56,520,000 | 2.41% |
| Rock Springs Capital Management LP | 2,499,148 | $70,626,000 | 1.82% |
| Ikarian Capital, LLC | 178,100 | $5,033,000 | 1.00% |
| Hood River Capital Management LLC | 896,572 | $25,337,000 | 0.97% |
| Frazier Life Sciences Management, L.P. | 393,000 | $11,106,000 | 0.86% |
| HighVista Strategies LLC | 23,611 | $667,000 | 0.38% |
| FEDERATED HERMES, INC. | 3,313,333 | $93,635,000 | 0.27% |